|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.69(B) |
Last
Volume: |
1,031,697 |
Avg
Vol: |
1,398,626 |
52
Week Range: |
$76.22 - $100.3 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
92,341 |
116,105 |
269,465 |
610,463 |
Total Sell Value |
$8,237,699 |
$10,489,308 |
$24,880,826 |
$57,517,351 |
Total People Sold |
3 |
4 |
5 |
8 |
Total Sell Transactions |
9 |
11 |
22 |
59 |
End Date |
2023-12-28 |
2023-09-26 |
2023-03-28 |
2022-03-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Wood Mark |
VP, Human Resources |
|
2013-05-22 |
4 |
OE |
$14.39 |
$72,405 |
D/D |
3,103 |
23,380 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-21 |
4 |
AS |
$64.14 |
$128,279 |
I/I |
(2,000) |
30,609 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-21 |
4 |
OE |
$12.99 |
$25,980 |
I/I |
2,000 |
32,609 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-17 |
4 |
OE |
$64.01 |
$320,050 |
I/I |
5,000 |
30,609 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-16 |
4 |
OE |
$12.99 |
$349,247 |
I/I |
7,000 |
25,609 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-16 |
4 |
AS |
$64.65 |
$129,307 |
I/I |
(2,000) |
20,609 |
|
- |
|
Bate Kenneth |
Director |
|
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
8,675 |
|
- |
|
Meier Richard A |
Director |
|
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
22,050 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,600 |
54,973 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
13,200 |
46,200 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,400 |
50,108 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
62,262 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,200 |
8,860 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,400 |
15,670 |
|
- |
|
Young William D |
Director |
|
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
8,675 |
|
- |
|
Lewis Alan |
Director |
|
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
19,300 |
|
- |
|
Lawlis V Bryan |
Director |
|
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
14,300 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
37,800 |
125,901 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-15 |
4 |
AS |
$68.55 |
$685,477 |
I/I |
(10,000) |
20,609 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-05-15 |
4 |
OE |
$12.99 |
$129,900 |
I/I |
10,000 |
30,609 |
|
- |
|
Heron Elaine J |
Director |
|
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
17,425 |
|
- |
|
Grey Michael G |
Director |
|
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
23,050 |
|
- |
|
Lapalme Pierre |
Director |
|
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
28,050 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2013-05-14 |
5 |
GA |
$0.00 |
$0 |
I/I |
1,912 |
10,955 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2013-05-14 |
5 |
GD |
$0.00 |
$0 |
D/D |
1,912 |
60,350 |
|
- |
|
1303 Records found
|
|
Page 9 of 53 |
|
|